Pricing Log in Create free account

DiaMedica Therapeutics, Inc. (DMAC) vs Rezolute, Inc. (RZLT)

DiaMedica Therapeutics, Inc. and Rezolute, Inc. are both Biotechnology companies. DiaMedica Therapeutics, Inc. and Rezolute, Inc. are of similar size ($471.1M and $449.2M). Across the 8 metrics below, Rezolute, Inc. leads on 6 and DiaMedica Therapeutics, Inc. on 2.

Valuation

Metric DMAC RZLT Biotechnology median
P/E n/m n/m 8.56
P/S n/m n/m 10.17
P/B 11.58 5.04 2.34
Price to free cash flow n/m n/m 20.42
EV/EBITDA n/m n/m 0.69
EV/Sales n/m n/m 9.64
Earnings yield (8.74%) (15.57%) (29.41%)
Free cash flow yield (7.10%) (12.90%) (23.50%)

Profitability

Metric DMAC RZLT Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (114.62%) (59.04%) (56.66%)
Return on assets (98.18%) (53.82%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DMAC RZLT Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) (16.67%) 23.47% 30.08%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DMAC RZLT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.72 9.68 4.72
Net debt to EBITDA 1.70 1.26 0.96

Dividend

Metric DMAC RZLT Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric DMAC RZLT Biotechnology median
Market cap 449.20m 471.07m 151.40m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack